6-KThe Wire
Sanofi files 6-K
Filed Jun 22, 2026 · 11d ago · Accession 0001193125-26-276766
Plain English
Sanofi announced that its drug Tzield has been approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes. This report is a Form 6-K, which is a report of a foreign private issuer.
Filing details
- Company
- Sanofi
- Ticker
- SNY
- CIK
- 1121404
- Form type
- 6-K
- Filing date
- Jun 22, 2026
- Report date
- Jun 22, 2026
- Document
- d104835d6k.htm
- Size
- 36 KB